Cargando…

LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma

BACKGROUND: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin res...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Junbin, Gao, Jin, Chen, Qinnan, Zou, Weiyan, Yang, Fen, Wei, Chenchen, Wang, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519870/
https://www.ncbi.nlm.nih.gov/pubmed/33061421
http://dx.doi.org/10.2147/OTT.S244879
_version_ 1783587660551421952
author Wang, Junbin
Gao, Jin
Chen, Qinnan
Zou, Weiyan
Yang, Fen
Wei, Chenchen
Wang, Zhaoxia
author_facet Wang, Junbin
Gao, Jin
Chen, Qinnan
Zou, Weiyan
Yang, Fen
Wei, Chenchen
Wang, Zhaoxia
author_sort Wang, Junbin
collection PubMed
description BACKGROUND: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD). MATERIALS AND METHODS: Cisplatin-resistant A549/DDP cells were generated by treatment with cisplatin by dose escalation. LINC01116 expression was compared between A549 and A549/DDP cells, and between cisplatin-resistant and non-resistant LAD specimens. The cell viability, colony formation, proliferation, migration and invasion were measured using MTT and Transwell assays, and cell apoptosis and cell cycle were detected using flow cytometry. The expression of E-cadherin and Vimentin was quantified. LAD xenografts were modeled in nude mice to investigate the role of LINC01116 on the resistance of LAD to cisplatin. RESULTS: MTT assay measured the IC(50) values of 13.49 ± 1.62 and 3.52 ± 1.33 μg/mL for A549/DDP and A549 cells, respectively. LINC01116 was overexpressed in cisplatin-resistant LAD specimens and A549/DDP cells (P < 0.05). Knockdown of LINC01116 inhibited cell viability, proliferation, migration and invasion, promoted apoptosis and enhanced the sensitivity to cisplatin in A549/DDP cells, while LINC01116 overexpression promoted cell viability, proliferation, migration and invasion, inhibited apoptosis and reduced the sensitivity to cisplatin in A549 cells. LINC01116 knockdown resulted in a 2.1-fold increase in E-cadherin expression and a 56% reduction in Vimentin expression in A549/DDP cells, and LINC01116 overexpression resulted in a 45% reduction in E-cadherin expression and a 1.82-fold increase in Vimentin expression in A549 cells. CONCLUSION: Dysregulation of lncRNA LINC01116 expression results in resistance of LAD to cisplatin via the EMT process. Our findings support the oncogenic role of LINC01116 to promote the development of cisplatin resistance in LAD, and LINC01116 may be a novel predictor of poor response to cisplatin.
format Online
Article
Text
id pubmed-7519870
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75198702020-10-14 LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma Wang, Junbin Gao, Jin Chen, Qinnan Zou, Weiyan Yang, Fen Wei, Chenchen Wang, Zhaoxia Onco Targets Ther Original Research BACKGROUND: Long non-coding RNAs (lncRNAs) have been found to contribute to cisplatin resistance in several cancers; however, the role of lncRNA LINC01116 in cisplatin resistance remains unknown in non-small-cell lung cancer. This study aimed to examine the contribution of LINC01116 to cisplatin resistance in lung adenocarcinoma (LAD). MATERIALS AND METHODS: Cisplatin-resistant A549/DDP cells were generated by treatment with cisplatin by dose escalation. LINC01116 expression was compared between A549 and A549/DDP cells, and between cisplatin-resistant and non-resistant LAD specimens. The cell viability, colony formation, proliferation, migration and invasion were measured using MTT and Transwell assays, and cell apoptosis and cell cycle were detected using flow cytometry. The expression of E-cadherin and Vimentin was quantified. LAD xenografts were modeled in nude mice to investigate the role of LINC01116 on the resistance of LAD to cisplatin. RESULTS: MTT assay measured the IC(50) values of 13.49 ± 1.62 and 3.52 ± 1.33 μg/mL for A549/DDP and A549 cells, respectively. LINC01116 was overexpressed in cisplatin-resistant LAD specimens and A549/DDP cells (P < 0.05). Knockdown of LINC01116 inhibited cell viability, proliferation, migration and invasion, promoted apoptosis and enhanced the sensitivity to cisplatin in A549/DDP cells, while LINC01116 overexpression promoted cell viability, proliferation, migration and invasion, inhibited apoptosis and reduced the sensitivity to cisplatin in A549 cells. LINC01116 knockdown resulted in a 2.1-fold increase in E-cadherin expression and a 56% reduction in Vimentin expression in A549/DDP cells, and LINC01116 overexpression resulted in a 45% reduction in E-cadherin expression and a 1.82-fold increase in Vimentin expression in A549 cells. CONCLUSION: Dysregulation of lncRNA LINC01116 expression results in resistance of LAD to cisplatin via the EMT process. Our findings support the oncogenic role of LINC01116 to promote the development of cisplatin resistance in LAD, and LINC01116 may be a novel predictor of poor response to cisplatin. Dove 2020-09-22 /pmc/articles/PMC7519870/ /pubmed/33061421 http://dx.doi.org/10.2147/OTT.S244879 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Junbin
Gao, Jin
Chen, Qinnan
Zou, Weiyan
Yang, Fen
Wei, Chenchen
Wang, Zhaoxia
LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title_full LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title_fullStr LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title_full_unstemmed LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title_short LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma
title_sort lncrna linc01116 contributes to cisplatin resistance in lung adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519870/
https://www.ncbi.nlm.nih.gov/pubmed/33061421
http://dx.doi.org/10.2147/OTT.S244879
work_keys_str_mv AT wangjunbin lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT gaojin lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT chenqinnan lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT zouweiyan lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT yangfen lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT weichenchen lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma
AT wangzhaoxia lncrnalinc01116contributestocisplatinresistanceinlungadenocarcinoma